



Original Research

Characterizing intrinsic molecular features of the immune subtypes of salivary mucoepidermoid carcinoma

Hyundeok Kang^{a,1}, Mi-Kyoung Seo^{a,1}, BeumJin Park^a, Sun Och Yoon^c, Yoon Woo Koh^b, Dahee Kim^{b,*}, Sangwoo Kim^{a,*}

^a Department of Biomedical Systems Informatics, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea

^b Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

^c Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

ARTICLE INFO

Keywords:

Salivary mucoepidermoid carcinoma
Immunophenotypic features
Tumor immune microenvironment
Lipid metabolism regulator
Immunotherapy

ABSTRACT

Introduction: Characterizing the tumor microenvironment (TME) and immune landscape of cancer has been a promising step towards discovering new therapeutic biomarkers and guiding precision medicine; however, its application in mucoepidermoid carcinoma (MEC) has been sparse. Here, we conducted a comprehensive study to understand the properties of the TME and immune profiles of MEC.

Method: 20 patients with MEC were collected from Yonsei Head and Neck Cancer Centre, Yonsei University, South Korea. Total RNA sequencing was conducted to determine gene expression profiles. Bioinformatic and immunoinformatic analyses were applied to characterize the TME and identify immunophenotypic subgroups, and to investigate the molecular features that explain the distinct phenotypes.

Results: The MEC samples were subdivided into two groups, immune hot and immune cold, based on the heterogeneous immune cell-infiltration and activation level. The immune-hot subgroup exhibited a higher level of immune activity, including T cell infiltration, cytolytic score, IFN- γ , antigen-presenting machinery, and immune modulator genes. Further characterizing molecular features of two subgroups, downregulation of lipid metabolic regulators, including MLXIPL and FASN, and the migration of chemokines and leukocytes were observed, respectively. And, Group-specific expression of immune checkpoint molecules, such as TIGIT, PD-L2, and CTLA-4, was observed in the immune-hot group, which can be exploited as a potential immunotherapeutic biomarker.

Conclusions: Immunophenotypically heterogeneous MEC subgroups analysis has shown distinctive molecular characteristics and provided potential treatment options. These findings yield new insights into TME of MEC and may help next step to study this uncharted cancer.

Introduction

Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of the salivary gland, accounting for approximately 30–40% of all malignancies [1]. MEC arises from heterogeneous cell types, including epidermoid, mucus-producing cells, and their intermediate cells [1]. Patients with MEC generally show a relatively good prognosis,

with a 5-year survival rate of 88.6% [1]. However, poor prognosis factors such as age, vascular invasion, cytologic atypia, and high mitotic frequency, affect treatment efficiency; for instance, about 25% of the high-grade MECs eventually recur, limiting the 5-year survival rate to 50–56% [1]. Over the years of cumulative salivary gland tumor management knowledge, multidisciplinary management approaches have been regarded as essential elements in MEC treatment, which includes

Abbreviations: CNV, copy number variations; CYT, cytolytic score; DEG, differentially expressed gene; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; GO, gene ontology; GTF, gene transfer format; GSVA, gene set variation analysis; IM, immunomodulator; IIS, immune infiltration score; MAF, mutation annotation format; MEC, mucoepidermoid carcinoma; NCCN, National Comprehensive Cancer Network; PPI, protein-protein interaction; ssGSEA, single-sample gene set enrichment analysis; TIS, T-cell infiltration score; TMB, tumor mutational burden; TME, tumor microenvironment; VEP, variant effect predictor; VST, variance-stabilizing transformation.

* Corresponding authors.

E-mail addresses: dhk@yuhs.ac (D. Kim), swkim@yuhs.ac (S. Kim).

¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.tranon.2022.101496>

Received 22 May 2022; Received in revised form 18 July 2022; Accepted 22 July 2022

1936-5233/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

surgical options as first choice of treatment with or without adjuvant therapy, to maximize the treatment outcome and maintain acceptable level of safety [2]. And, with recent advancement of machine learning techniques, decision tree based adjuvant chemo treatment prognosis predictive model has shown promising personalized treatment options for salivary cancer patients [3]. However, unlike many other major cancers that have benefitted from genomics-based biomarker development, patient stratification, and precision medicine, the rarity and lack of underlying molecular/genomic characterization hinder the use of such advances in MEC. Only a few driver mutations are known for MEC, including the t(11;19) translocation, which involves fusion of the transcriptional coactivator genes *MAML2* and *CRTC1* [4], copy number variations (CNVs) in *DCC*, *SMAD4*, and *GALR1* [5] and additional somatic mutations in *TP53* and *POU6F2* [6]. Except for the *CRTC1-MAML2* fusion, which is known to have a favorable prognosis [4], no major genetic aberrations have been associated with or utilized for clinical use. As the discovery of novel high-frequency mutations is unlikely, alternative approaches with possible clinical implications are required for better treatment of MEC.

Recent advances in the profiling of immune cells and the tumor microenvironment (TME) and understanding the interplay between tumors and their surrounding components have led to warrant new therapeutic opportunities for immune-oncology, such as immune checkpoint blockades, discovery of new biomarkers for improved prognosis, and optimization of clinical management [7–9]. In salivary gland cancer, these efforts have been described in recent research [10]. However, comprehensive TME landscape of MEC has not yet been elucidated.

In the present study, based on the level of immune and stromal cell infiltration, we characterized the tumor immune microenvironment of MEC using whole transcriptome analysis of 20 tumor samples. Furthermore, gene expression and protein interaction networks analysis revealed immunophenotypic subgroup-associated intrinsic molecular features and potential immunotherapeutic biomarkers. We expect that our study will provide insights to next step of immuno-oncologic research of MEC.

Material and methods

Sample acquisition and preparation

Twenty patients who were diagnosed with MEC and treated at the Yonsei Head and Neck Cancer Center between March 2012 and April 2018, were enrolled in the study. Fresh frozen tissues from primary MECs and their matched normal tissues were retrieved and collected during the operation, after approval by the Institutional Review Board at Severance Hospital, Yonsei University College of Medicine (IRB 255-001). Informed written consents were obtained from all patients. The inclusion criteria were as follows: (1) patients aged > 18 years; (2) patients with biopsy-proven MEC with a minimum diameter of 1 cm (to get sufficient amount of tissue sample without violating margin finding, which determines for adjuvant therapy); and (3) patients with no previous history of chemotherapy or radiotherapy. All patients were treated surgically by complete resection, according to the National Comprehensive Cancer Network (NCCN) guidelines. The general clinical characteristics of the patients are presented in Table 1.

Data processing

FastQC (version 0.11.7) was used to determine read quality. No further read trimming and filtering were performed. Reads obtained from RNA sequencing were mapped against the UCSC hg38 reference genome (FASTA) and hg38 gene annotation (GTF) using STAR (version 2.6.0c) [11] under two default passes. The resulting alignment files (BAM) were used to quantify the read count per gene, using HTSeq (version 0.10.0) [12]. All count data were normalized using the DESeq2 software package (version 1.24.0) [13] to normalize the raw counts into

Table 1
The clinical and pathological characteristics of mucoepidermoid carcinoma patient.

	MEC 1	MEC 2	MEC 3	MEC 4	MEC 5	MEC 6	MEC 7	MEC 8	MEC 9	MEC 10	MEC 11	MEC 12	MEC 13	MEC 14	MEC 15	MEC 16	MEC 17	MEC 18	MEC 19	MEC 20
Sex	M	M	F	F	M	M	M	F	M	M	F	F	F	F	F	F	F	M	M	M
Age	33	28	30	64	63	31	51	70	18	79	55	80	48	55	66	24	58	52	47	67
Primary site	PG	PG	PG	PG	PG	PG	PG	PG	SG	PG	SM	PG	SM	MS	MS	MS	PG	PG	PG	MS
Size(mm)	34	18	25	25	23	45	24	15	15	29	17	15	21	12	40	15	14	38	12	36
Grade	L	L	L	H	L	L	L	L	L	H	L	L	H	L	L	L	L	L	L	L
Perineural invasion	+	+	-	-	-	-	+	-	-	+	-	-	-	-	-	+	+	+	+	-
Nodal involvement	+	+	-	-	-	-	+	-	-	+	-	-	-	-	-	+	+	+	-	-

MEC: mucoepidermoid carcinoma; M: male; F: female; PG: Parotid gland; SG: Sublingual gland; SM: Submandibular gland; MS: Minor salivary gland; L: low; H: high.

variance-stabilizing transformation (VST).

Calculation of TME

For constructing concise TME genes specific to microenvironment-related cells, gene signatures from CIBERSORT [14] and MCP-counter [15] were used. All 22 gene signature sets (LM22) of CIBERSORT were utilized; however, as they do not cover fibroblast and endothelial cell gene signatures, these were imported from the MCP-counter. Subsequently, using the gene set variation analysis (GSVA) software package (version 1.32.0) [16] single-sample gene set enrichment analysis (ssGSEA) function, a ssGSEA was performed on normalized expression data to measure the abundance of each cell subset in each patient.

Tumor subgrouping with TME estimation

ssGSEA was used to measure the abundance of immune and microenvironmental cells in the sample, using the ssGSEA function of the GSVA software package (version 1.32.0) [16]. In total, 24 cell types were investigated by combining two gene signatures: the LM22 signature of CIBERSORT [14] for 22 major immune cell types, and MCP-counter [15] to supplement two microenvironmental cell types: fibroblasts and endothelial cells. Based on the ssGSEA scores, hierarchical clustering was performed using Euclidean distance and complete linkage methods utilizing the ComplexHeatmap software package (version 2.0.0) [17]. The two largest clusters were used to define two immunologically distinct subgroups, which were later designated as immune-hot and immune-cold subgroups.

Robustness of the subgroups was tested by constructing clusters with an independent TME score from ESTIMATE (version 2.0.0) [18]. To produce ESTIMATE scores, T-cell infiltration score (TIS), immune infiltration score (IIS), cytolytic score (CYT), and IFN- γ score were calculated as follows [19]: (1) TIS was defined as the mean of the standardized values for CD8⁺ T, central memory T, and effector memory T cells, and Th1, Th2, Th17, and Treg cells; (2) IIS of a sample was defined as the mean of the standardized values for macrophages, DC subsets (total, plasmacytoid, immature, and activated), B cells, cytotoxic cells, eosinophils, mast cells, neutrophils, NK cell subsets (total, CD56bright, and CD56dim), and all T-cell subsets excluding T-gamma delta and T-follicular helper cells; (3) CYT score was calculated from the geometric mean of the expression of granzyme A (*GZMA*) and perforin (*PRF1*), which was demonstrated in the study by Rooney et al. [20]; and, (4) IFN- γ signalling was scored with ssGSEA using the IFN- γ gene set defined in REACTOME (Error! Hyperlink reference not valid. INTERFERON_GAMMA_SIGNALING).

Comparative analysis of subgroups

Differential gene expression analysis between the immune-hot and cold subgroups was determined using the following significance criteria: (1) adjusted $P < 0.05$, and 2) $\text{Log}_2(\text{fold change}) \geq 1$, using the internally implemented function of the DESeq2 software package (version 1.24.0) [13]. Gene ontology (GO) and pathway enrichment analyses were performed using the clusterProfiler software (version 3.12.0) [21]. For subtype tumor intrinsic analysis, differentially expressed gene (DEG) analysis was performed using the following significance criteria: (1) adjusted $P < 0.01$, and (2) $\text{Log}_2(\text{fold change}) \geq 3$. For the gene set enrichment analysis (GSEA), genes were ranked by their log fold-exchange values, then GSEAPreanked with default settings was used [22] and the 50 hallmark genes from MSigDB collection were utilized [23]. The enrichment score (ES) denotes which gene set is overrepresented at the top or bottom of the ranked gene list.

Analysis of isoform switching

HISAT2 (version) [24] was used to quantify the transcript-level

expression of the UCSC hg38 reference. The mapped transcripts were assembled using Stringtie [24] and used for downstream analysis. Alternative splicing and isoform changes in normal to tumor progression were examined using IsoformSwitchAnalyzeR (version 1.8.0) [25] at default setting and per the recommended procedures in the manual. To assess the protein-coding potential of transcripts, CPC2 (<http://cpc2.cbi.pku.edu.cn/batch.php>) (web version 2.0) was used. Protein domains were predicted using HMMER (<https://www.ebi.ac.uk/Tools/hmmer/search/hmmscan>) (web-version 2.41.1), and PFAM was used as a profile database. Signal peptides were predicted using SignalP-5.0 (<http://www.cbs.dtu.dk/services/SignalP>) (web-version 5.0) with eukaryote and short-output options.

Network-based functional analysis of genes

The significant candidate genes were identified using the STRING database [26]. A combined score of ≥ 0.4 was used as the cut off for a significant interaction. We developed a network of isoform-switched genes and PPIs. To visualize the protein interaction network and analyze hub proteins, the CytoHubba application [27] in Cytoscape (v.3.7.2) [28] was utilized to implement seven calculation methods: degree, bottleneck, closeness, betweenness, eccentricity, EPC, and MCC.

Results

Immunological subgrouping of MECs

We initially profiled the tumor microenvironment in 20 patients with MEC from Yonsei Head and Neck Cancer Center (Table 1) using ssGSEA with respect to 24 immune and stromal cell types (Fig. 1A) (see Materials and methods for analysis procedures and Fig. S1 for overall workflow). Hierarchical clustering of the 20 MECs with the inferred cell abundance revealed two subgroups: eight tumors with high immune cell infiltration (referred to as immune-hot) and 12 with low infiltration (immune-cold). The infiltration patterns were concordant among most immune cell types, including myeloid progenitor cells, NK/T lineage cells, and stromal cells, with only a slight variation in B and mast cells. In addition, we confirmed that these clusters were consistently reproduced in an independent analysis with a different measurement algorithm (ESTIMATE [18], see Materials and methods), showing clear immunological discrepancies between the two subgroups (Fig. 1A and Table S1) (Wilcoxon rank-sum test, $P = 4.5 \times 10^{-4}$ for immune score and $P = 6.0 \times 10^{-4}$ for stromal score, see Materials and methods). These results represent immunological heterogeneity and the existence of subgroups of MECs.

Further analyses confirmed distinct immune activities between the subgroups. The expression levels of *CD8A* and *CD8B* were significantly higher in the immune-hot MECs (Fig. 1B, Wilcoxon rank-sum test $P = 1.1 \times 10^{-3}$ for *CD8A* and $P = 3.0 \times 10^{-3}$ for *CD8B*) than in the immune-cold MECs, demonstrating distinct activities of cytotoxic T-cells. Similarly, scores for TIS (i.e. the average value of central memory, effector memory CD4⁺ and CD8⁺ T cells, and Th1, Th2, Th17, and Treg cells), and overall IIS [19] were high in immune-hot MECs (Wilcoxon rank-sum test $P = 3.2 \times 10^{-5}$ for TIS and $P = 6.4 \times 10^{-5}$ for IIS). Moreover, we noted elevation in the CYT score ($P = 4.1 \times 10^{-3}$) [20] and IFN- γ score ($P = 3.0 \times 10^{-4}$) [29] (see Materials and methods) for the immune-hot group (Fig. 1C). After observing high levels of immune infiltration and immunity in the immune-hot group, we further characterized the immunophenotypes of the two MEC subgroups, focusing on the correlation between immune-cell infiltration and cytotoxic functions. IFN- γ , one of the final products of antitumor T-cell activity, was strongly positively correlated with the TIS (Pearson correlation coefficient $r = 0.76$, $P = 1.0 \times 10^{-4}$) and overall IIS ($r = 0.84$, $P = 3.1 \times 10^{-6}$; Fig. S2B). Together, these results suggested that immune cell infiltration and activity level-based MEC stratification exhibited two robust immunophenotypic subgroups.




Fig. 1. Comprehensive immune landscape and immune modulator illustration representing immune subtypes of MEC. **A.** Single-sample genaset enrichment analysis (ssGSEA) of 20 patients with MEC identified two immunophenotypically distinctive subgroups based on different immune and stromal cell-infiltration levels. Top bar plot represents the number of gene mutations in each sample. **B.** Comparison of CD8A and CD8B expression between the immune-hot and -cold MEC. **C.** Comparison of the TIS, IIS, INFG, CYT, and APM scores between the immune-hot and -cold MEC. Statistics in A–C: Wilcoxon test. All *P*-values for significance < 0.05.

Subgroup-associated immunophenotypic characteristics

We then investigated the phenotypic characteristics that confer immunological differences between the immune-hot and -cold subgroups. We initially noted that the TMB and neoantigen burden did not differ between the subgroups (Wilcoxon rank-sum test, $P = 5.7 \times 10^{-1}$ and $P = 6.8 \times 10^{-1}$ for immune-hot and -cold subgroups, respectively). The frequency and pattern of known MEC prognosis associated marker [30], *CRTC1-MAML2* fusion, was not significantly different between immune subgroups (6/8 and 6/12 in immune-hot and -cold, respectively, Fisher's exact test, $P = 3.7 \times 10^{-1}$), and, no potential immunogenic neoantigens were predicted by the *CRTC1-MAML2* fusion event (see Supplementary Materials and methods). The schematic diagram of fusion gene structure is illustrated Fig. S3. Based on these results, we presumed that the immunological differences between subgroups resulted from the machinery or regulatory mechanisms in the immunity cycle, rather than genome-level aberrations.

Next, to profile the activities of subgroup-associated immune-regulatory mechanisms, expression levels of 78 immunomodulator (IM) genes [9] were used to infer the status of seven immune regulatory categories: antigen presentation, cell adhesion, immune checkpoint receptor, ligand, co-inhibitor, co-stimulator, and others (Fig. 2). We found that most of the IM genes and the categories, particularly cell adhesion (*SELP*, *ITGB2*, and *ICAM1*), antigen presentation (HLA Class I/II), co-inhibitor (PD-L1, PD-L2, *BTN3A1*, and *BTN3A2*), co-stimulator (*CD80* and *CD28*), and ligand (*CXCL9*, *CXCL10*, *IL2*, *IL10*, *OX40L*, *CD40LG*, and *IFNG*), were consistently elevated in the immune-high MECs (all, $P < 5.0 \times 10^{-2}$), which implied that the immunologic differences may have risen at the early stages of the immunity cycle, such as the antigen-presenting machinery (APM). Of note, level of the APM [29] was significantly low in the immune-cold subgroup ($P = 7.3 \times 10^{-3}$) compared to that in the immune-hot subgroup (Fig. S2A), and was positively correlated with the TIS ($r = 0.56$, $P = 9.5 \times 10^{-3}$) and IIS ($r = 0.67$, $P = 1.1 \times 10^{-3}$) (Fig. S2C). These results indicate that the higher cytolytic potential in the immune-hot MECs could be a result of the higher level of APM expression with a cytolytic feed-forward loop along with an increased amount of immune cell infiltration, thereby leading to elevated IFN- γ levels and anti-cancer immune activity.

Transcriptomic landscape and hub genes of the immune subgroups

To illustrate the biological properties of immune-hot and immune-cold MECs, we conducted a functional analysis in the biological contexts based on gene expression profiles. We identified 1518 DEGs between the two subgroups, 1076 of which were upregulated in the immune-hot and 442 in the immune-cold MECs (see Materials and methods). Gene ontology (GO)-based enrichment analysis (see Materials and methods) uncovered a global overrepresentation of innate and adaptive immune-related terms in the immune-hot subgroup, including T-cell activation, regulation of leukocyte activation, and regulation of lymphocyte activation (all, adjusted $P < 1.0 \times 10^{-2}$) (Fig. S4A, top). Likewise, cancer hallmark-based GSE analysis (see Materials and methods) revealed enrichment of inflammatory response and interferon-gamma response in the immune-hot MECs, confirming increased anti-tumor immune activity (Fig. S4B). For the immune-cold MECs, ion transport-related terms, epidermis development, cornification, and chloride transport from GO analysis (all, adjusted $P < 1.0 \times 10^{-2}$) (Fig. S4A, bottom), and metabolism-related cancer hallmark, such as fatty acid metabolism and adipogenesis, were enriched (Fig. S4C).

Next, to improve understanding of factors that are shaping heterogeneity of immune state in MEC immune subgroups, we sought to assess tumor-intrinsic traits of them by comparing with matched adjacent normal tissues. First, we identified 893 DEGs with tumor-specific expression (see Materials and methods). Of these, 467 DEGs were over- or under-expressed from immune-hot MECs tumor and 326 from immune-cold MECs (full list available in Tables S2–S5). As the top-

ranked upregulated genes observed only in immune-hot MEC, *CXCL13*, which is a B cell chemoattractant and an important factor in TLS formation and initiation of secondary lymphoid organ development [31] (adjusted $P = 1.55 \times 10^{-10}$ and log2 fold change 5.89) and *DUOX2*, responsible for the innate immune response [32] (adjusted $P = 2.74 \times 10^{-9}$ and log2 fold change 5.94), were observed, whereas *MUC6* (mucin 6) was top ranked in immune-cold MEC (adjusted $P = 1.34 \times 10^{-6}$ and log2 fold change 5.47). *POSTN1* (periostin), which affects tumor microenvironment remodeling during tumor progression, was one of the top-ranking genes overexpressed in both immune subgroups (log2 fold change > 5). Then, also, to integrate biological impact of isoform-level changes in forming polar tumor microenvironment, we measured the isoform switches as mentioned in Vitting-Seerup and Sandelin [25] and we identified 173 and 85 genes that underwent isoform switching in tumorigenesis in the immune-hot and -cold MECs, respectively. Among the 640 genes in immune-hot MECs, we identified T-cell regulatory genes (*ADA*, *IL4R*, and *NFKBIZ*) and lipid metabolism regulatory genes (*MLXIPL*, *LEP*, and *FASN*). From 411 genes from immune-cold MECs, we observed collagen and bone forming related genes (*MMP13*, *COL10A1*, and *ITGB6*) (see Materials and methods; full list available in Tables S6 and S7). These gene- and isoform-level intrinsic features provide a broad understanding of the distinctive intrinsic features that reflect the heterogeneous immunophenotypic state of each immune MEC subgroup.

To better study the functional significance of subgroup-specific genes at the system level, we constructed Protein-protein interaction (PPI) network by the union of DEGs and significant isoform-switching genes (Table S8), which formed 610 nodes and 1429 edges, and 403 nodes and 896 edges for immune-hot and -cold subgroups, respectively (Table S9). We then selected hub genes, important nodes with several interaction partners, with seven different topological analysis algorithms provided by cytoHubba [27], which appeared more than twice in the union of all top 20 genes from each algorithm, resulting in 35 genes (15 upregulated and 20 downregulated) and 31 genes (2 upregulated and 29 downregulated; Table S10) for immune-hot and -cold subgroups, respectively, and then searched for their functionality.

In the immune-hot MECs, the genes that are related to chemokine regulation and ECM (*POSTN*, *COL11A1*, *MMP13*, *LUM*, *VCAN*, and *BGN*) and lipid metabolism regulation (*SCD*, *LPL*, *MLXIPL*, *PCK1*, and *DGAT2*) were selected as hub genes (Fig. 3A). Overexpression of the ECM-related genes and lipid metabolism-related genes in cancers is associated with cancer progression, immune suppression, and tumor aggressiveness [33, 34]. Here, as expected, ECM-related genes were over-expressed in the immune-hot MECs; however, lipid metabolic-regulator genes were under-expressed in the immune-hot MECs, and this particular feature, downregulated lipid metabolism, was also captured in above GSE analysis. Based on the aforementioned findings and inverse correlation between signature scores of fatty acid metabolism and adipogenesis obtained from cancer hallmark genesets with cytotoxic activity (Spearman correlation coefficient $r = -0.49$, $P = 3.1 \times 10^{-2}$ and $r = -0.55$, $P = 1.4 \times 10^{-2}$, respectively; Fig. 3B), we surmised that under-expressed lipid metabolic regulator genes in immune-hot MEC samples could be novel molecular characteristics and may be linked to agonistic anti-tumor immune activity in this MECs, as their over-expression is often related to a decrease in immune activity [34,35]. In the immune-cold MEC samples, all selected genes, except *POSTN* and *RUNX2*, were downregulated and are known to function as chemokines and their receptors (*CXCR1*, *CXCR2*, *CCL2*, *CCR3*, and *CCR10*) and in leukocyte migration and adhesion (*ELANE*, *LEP*, and *SELL*) (Fig. 3C).

Additionally, *POSTN* and *RUNX2* were recurrently overexpressed in tumor samples from both MEC immune subgroups. *POSTN* participates in ECM structure formation and organization [36,37], and *RUNX2* is a key transcription factor for osteoblast differentiation [38]. At this point, we do not know their exact roles in MECs; however, based on our observations and previous studies, we conjecture that they could play a critical role in MEC ECM formation. In this analysis, we identified unique and common candidate molecular characteristics that were




Fig. 2. Comparison of immunomodulator genes between the two immune MEC subgroups. Comparison of immune modulatory regulator genes between the immune-hot and -cold MEC. Statistics: Wilcoxon test. P-values for significance < 0.05.




Fig. 3. . PPI network and Hubgene analysis. **A.** Hubgenes were selected from the DEGs and IS genes from immune-hot MEC tumor intrinsic analysis. Genes were grouped into functionally similar GO terms. The size of GO term indicates the number of genes matched to the term, with the greater number of gene being larger. Colors of genes represent the following: Red: DE up; Violet: IS up; Blue: DE down; Sky blue: IS down. **B.** Correlation between GSEA identified significantly enriched 'Hallmark fatty acid metabolism' and 'Hallmark adipogenesis' with CTY score. **C.** Immune-cold MEC tumor intrinsic analysis. Genes were grouped into functionally similar GO terms. The size of GO term indicates the number of genes matched to the term, with the greater number of genes being larger. Colors of genes represent: Red: DE up; Violet: IS up; Blue: DE down; Sky blue: IS down. Statistics in A and C: GO term analysis. All q -values for significance < 0.05 and significant fold change (FDR < 0.01). R values represent the Pearson correlation coefficients.

predicted to play a vital role in immune regulation and intrinsic tumor characteristics of two immunophenotypically distinct MECs. Further studies are warranted to better understand their role in MECs and their potential use as targets for novel classification and therapeutic implications.

Molecular features associated with immuno-oncology therapeutics

Based on the subgrouping and immunological analyses, we explored potential subgroup-specific molecular features that can be employed in the application of current immunotherapy to MECs. First, we examined the efficacy of immune checkpoint inhibitors (ICIs). The analysis of mRNA expression identified significant elevation of PD-1 and PD-L1 levels in the immune-hot MECs ($P = 9.6 \times 10^{-3}$ and $P = 3.1 \times 10^{-2}$) (Fig. 4A). In addition, co-inhibitor genes, including *SLAMF7* ($P = 1.0 \times 10^{-2}$), *BTN3A1* ($P = 1.0 \times 10^{-4}$), and *BTN3A2* ($P = 9.0 \times 10^{-3}$), were highly expressed in the immune-hot subgroup. Extended analysis of a collection of immuno-oncological therapy biomarkers [39] with the immune-hot subgroup-specific DEGs identified elevated levels of additional immune checkpoint molecules (*TIGIT*, *4-1BB*, *TIM-3*, *PD-L2*, and *CTLA-4*), T-cell targeted immunomodulators (*ICOS*, *IL10*, and *OX40*), adaptive immune systems (*MICB*), and cell adhesion molecules (*ICAM1*) in the immune-hot MECs (Figs. 4B and S5A). These results suggest that at least a subgroup of immune-hot MECs underwent T-cell exhaustion by checkpoint molecules and could be sensitive to ICIs. In contrast, in the immune-cold MECs, carbonic anhydrase IX (*CA9*), a surrogate marker of hypoxia-related response [40], and the Wnt signaling signal transduction regulators Dickkopf-1 (*DKK1*), which functions to confer tumor growth and metastasis [41], Ring Finger Protein 43 (*RNF43*), cytokine signaling regulator RANK (*TNFRSF11A*), and cell tight junction-associated claudin 3 (*CLDN3*) were highly activated (Figs. 4B and S5B). This suggests that different or combined therapeutic strategies are needed as the subgroups based on immune activity show distinct immunosuppressive TME characteristics.

Discussion

In recent years, remarkable success of immunotherapy in cancer treatment has triggered tumor immune microenvironment research in other cancer type [29]. With such efforts, understanding of how tumors interact with their surrounding environment has been broadened and utilized in prognosis assessment, treatment planning, and clinical outcome predictions. However, such efforts have been neglected with regard to MECs. Here, we made the first attempt to discover the molecular features that could be used in precision medicine and potential treatment biomarkers of MEC by landscaping its tumor immune microenvironment and analyzing the intrinsic characteristics of its immunophenotypic subgroups.

In this study, we demonstrated two immunophenotypically heterogeneous MECs based on the estimated immune and stromal cell-infiltration abundance levels in tumor microenvironment. For immune-hot MECs, elevated immune activity (TIS and IIS score), expression level of the APM score, chemoattractants required for trafficking of T cells to tumors (*CXCR9* and *CXCR10*), cytokines (*TNFSF9*, *IL2*, and *INFG*), and co-stimulators (*CD80* and *CD28*) were observed. Concomitantly, increased expression levels of immune co-inhibitors, such as PD-L1, PD-L2, *BTN3A1*, and *BTN3A2*, and immune checkpoint genes (*ICOS*, *OX40*, *TIM-3*, and *TIGIT*) were observed as well. In the context of the cancer-immune cycle, active tumor-antigen presenting has led to enhanced immune-cell trafficking and T-cell infiltration, resulting in successful anti-tumor immunity, and such dynamic pro-immune TMEs were captured in this group. In contrast, immune-cold MEC was impoverished in immune activation signatures and enriched with genes that are associated with ECM signatures, such as epidermis development, cornification, skin development, and epidermal cell differentiation. Based on these findings, along with downregulated APM


expression, we could infer that ineffective antigen-presenting mechanisms and over-expressed physical barriers prevent immune cell infiltration and promote immune evasion [33]. Additionally, based on the distinct tumor immune microenvironment profiles observed in the two MEC subgroups, we believe PD-1/PD-L1 blocking immune checkpoint molecules could render therapeutic benefits to immune-hot MEC patients, and that other potential immuno-oncological therapy targets could also be utilized in treating immune-hot and -cold MEC. We hope our findings will aid in future immuno-oncologic therapeutic treatments for immune-hot and -cold MECs and provide wider therapeutic treatment options for MEC patients.

As tumor cells require more energy than normal cells and are the elementary characteristics of every transforming cell, lipid accumulation serves as an energy source and provides cell membrane structural integrity [42]. Additionally, high activation of the lipid metabolic state in cancer is characterized by immune suppressive activity in the TME via enhancement of myeloid-derived suppressor cell activity and suppression of dendritic cells and *CD1D* [34,35,43]. By conducting a multi-step transcriptomic analysis, we discovered the intrinsic molecular characteristics of the two MEC immune subgroups. It delineated that in immune-hot MEC, lipid metabolic regulator genes, such as *MLXIPL* (also known as ChREBP), a key regulator of fatty acid synthesis and lipid metabolism, fatty acid synthase (*FASN*) and *stearoyl-CoA desaturase (SCD)*, were significantly downregulated. As they are known to dysregulate the TME at various levels and promote cancer growth levels [44], but based on our results, we believe that such findings may have contributed to forming elevated immune activity in immune-hot MEC, and further investigation is needed to ascertain the role of dysregulated lipid metabolism in immune-elevated MEC.

The *CRTC1-MAML2* fusion has been associated to favorable prognosis of MEC [45] and increased tumor-infiltrating immune activity also results in a favorable prognosis. Therefore, we initially anticipated that the *CRTC1-MAML2* fusion would be more significant in immune-hot MECs than in -cold MECs; however, in our study result, no significant association was shown between the subgroups (Fisher's exact test, $P = 0.37$). Based on this result, we must carefully consider a few reasons for this. First, although a higher proportion of fusion-positive patients was present in the immune-hot MEC subgroup (6/8 [75%] vs. 6/12 [50%]), our study sample size was not large enough to show a statistically significant difference between the two groups. Second, in this study, we performed *CRTC1-MAML2* neoantigen analysis, but *CRTC1-MAML2* fusion did not produce peptides with immunogenicity. This suggests that the *CRTC1-MAML2* fusion may not directly related to the immunogenic role or the immunophenotype of MEC. Additionally, gender has been a played significant role in MEC, with a female and male ratio of 2:1, and with a better prognosis (1). Therefore, we checked whether the gender-based immunophenotypic feature differences can be observed in our study samples. We performed inter and intra subgroup gender comparison statistical test to see whether there is significant difference between them (data not shown). However, gender was not significant indicator as well. Thus, although we cannot conclude the immunogenic role of *CRTC1-MAML2* and gender in MEC at this point, we might be able to do so with a larger cohort.

In this study, we discovered common molecular features that were overexpressed immune-hot and -cold subgroups compared to those in normal MEC immune subgroup samples, namely, *POSTN* and *RUNX2*. These are known to be overexpressed in bone development, maturation, and remodeling; epithelial-mesenchymal transition (EMT); ECM structuring and remodeling; and inflammatory processes. Their role as key regulators in such biological processes in other tumors has been well documented [46]. We speculate that the roles of *POSTN* and *RUNX2* in MEC are similar to those in previously studied tumors. However, further research is required to comprehensively understand their functional role and potential crosstalk in relation to the tumor immune microenvironment of MEC. It is worth mentioning that attempts have been made to target *POSTN* for new therapeutic options in other cancers, and we hope

a



b




Fig. 4. . Comparison of PD-1, PD-L1, and immuno-oncological (IO) target gene expression difference between the two immune MEC subgroups. **A.** Comparison of PD-1 and PD-L1 score between the immune-hot and -cold MEC subgroups. **B.** Heatmap showing expression of immuno-oncological therapeutic target genes between the immune-hot and -cold MEC subgroups. Upper part shows target genes that are differentially upregulated in the immune-hot MEC, and lower part shows target genes that are differentially upregulated in the immune-cold MEC. Statistics in A: Wilcoxon test. All P-values for significance < 0.05.

that the therapeutic value of *POSTN* in MEC will also be tested in the future.

Here, we aimed to demonstrate the heterogeneity of the tumor immune microenvironment of MEC and the intrinsic characteristics of each MEC subgroup and provide potential immunotherapeutic targets. Significantly downregulated lipid metabolic regulators and immune-related genes were among the most distinguishing characteristics of the immune-hot MEC and -cold MEC. We discovered potential immunotherapeutic targets that could be used in immune-inflamed MEC. This study has several limitations. Findings analyzed in a relatively small sample in this study will need to be validated in an independent cohort. And we were not able to perform prognostic analysis with our study samples due to limited sample size and short follow up period. Although this study suggests promising immune-oncology targets for each immune-based subgroup, this study has limitation in that it cannot derive meaningful results from prognostic analysis due to insufficient sample size and follow-up period. Thus, in future studies, a larger cohort size and longer follow-up period would provide us with more comprehensive knowledge and information on the role of our findings in MEC.

Ethics approval and consent to participate

The work was conducted after approval of Institutional Review Board at Severance Hospital, Yonsei University College of Medicine (IRB 255-001). Patient samples were collected after informed written consents were obtained from all patients.

Consent for publication

All the authors have given their consent for this publication.

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No. HI14C1324).

CRedit authorship contribution statement

Hyundeok Kang: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing – original draft, Visualization. **Mi-Kyoung Seo:** Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing – original draft, Visualization. **BeumJin Park:** Visualization. **Sun Och Yoon:** Resources, Formal analysis, Writing – review & editing. **Yoon Woo Koh:** Resources, Writing – review & editing. **Dahee Kim:** Writing – review & editing, Resources, Supervision, Project administration. **Sangwoo Kim:** Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Availability of data and materials

: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgment

None.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.tranon.2022.101496](https://doi.org/10.1016/j.tranon.2022.101496).

References

- [1] G.C. Janet-Ofelia, M.V. Rafael, G.A. Guillermo, C.V. Carlos-Enrique, R.M. Jose-Martin, G.M. Henry, et al., Mucoepidermoid carcinoma of the salivary glands: survival and prognostic factors, *J. Maxillofac. Oral Surg.* 16 (4) (2017) 431–437, <https://doi.org/10.1007/s12663-016-0946-y>.
- [2] F. De Felice, M. de Vincentiis, V. Valentini, D. Musio, S. Mezi, L. Lo Mele, et al., Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome head and neck unit clinical recommendations, *Crit. Rev. Oncol. Hematol.* 120 (2017) 93–97, <https://doi.org/10.1016/j.critrevonc.2017.10.010>.
- [3] F. Def, V. Valentini, M. Dev, C.R.T. Dig, D. Musio, A.A. Tummulo, et al., Prediction of recurrence by machine learning in salivary gland cancer patients after adjuvant (chemo)radiotherapy, *In Vivo* 35 (6) (2021) 3355–3360, <https://doi.org/10.21873/in vivo.12633>.
- [4] M.E. Perez-de-Oliveira, V.P. Wagner, A.L.D. Araujo, M.D. Martins, A.R. Santos-Silva, L. Bingle, et al., Prognostic value of CRTCl-MAML2 translocation in salivary mucoepidermoid carcinoma: systematic review and meta-analysis, *J. Oral Pathol. Med.* (2019), <https://doi.org/10.1111/jop.12970>.
- [5] K.J. Jee, M. Persson, K. Heikinheimo, F. Passador-Santos, K. Aro, S. Knuutila, et al., Genomic profiles and CRTCl-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma, *Mod. Pathol.* 26 (2) (2013) 213–222, <https://doi.org/10.1038/modpathol.2012.154>.
- [6] H. Kang, M. Tan, J.A. Bishop, S. Jones, M. Sausen, P.K. Ha, et al., Whole-exome sequencing of salivary gland mucoepidermoid carcinoma, *Clin. Cancer Res.* 23 (1) (2017) 283–288, <https://doi.org/10.1158/1078-0432.CCR-16-0720>.
- [7] S. Gnjatic, V. Bronte, L.R. Brunet, M.O. Butler, M.L. Disis, J. Galon, et al., Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy, *J. Immunother. Cancer* 5 (2017) 44, <https://doi.org/10.1186/s40425-017-0243-4>.
- [8] B. Mlecnik, G. Bindea, H.K. Angell, P. Maby, M. Angelova, D. Tougeron, et al., Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability, *Immunity* 44 (3) (2016) 698–711, <https://doi.org/10.1016/j.immuni.2016.02.025>.
- [9] V. Thorsson, D.L. Gibbs, S.D. Brown, D. Wolf, D.S. Bortone, Y.T.H. Ou, et al., The immune landscape of cancer, *Immunity* 51 (2) (2019) 411–412, <https://doi.org/10.1016/j.immuni.2019.08.004>.
- [10] M. Linxweiler, F. Kuo, N. Katabi, M. Lee, Z. Nadeem, M.G. Dalin, et al., The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype, *Clin. Cancer Res.* (2020), <https://doi.org/10.1158/1078-0432.CCR-19-3758>.
- [11] A. Dobin, C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, et al., STAR: ultrafast universal RNA-seq aligner, *Bioinformatics* 29 (1) (2013) 15–21, <https://doi.org/10.1093/bioinformatics/bts635>.
- [12] S. Anders, P.T. Pyl, W. Huber, HTSeq—a Python framework to work with high-throughput sequencing data, *Bioinformatics* 31 (2) (2015) 166–169, <https://doi.org/10.1093/bioinformatics/btu638>.
- [13] M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, *Genome Biol.* 15 (12) (2014) 550, <https://doi.org/10.1186/s13059-014-0550-8>.
- [14] A.M. Newman, C.L. Liu, M.R. Green, A.J. Gentles, W. Feng, Y. Xu, et al., Robust enumeration of cell subsets from tissue expression profiles, *Nat. Methods* 12 (5) (2015) 453–457, <https://doi.org/10.1038/nmeth.3337>.
- [15] E. Becht, N.A. Giraldo, L. Lacroix, B. Buttard, N. Elaroui, F. Petitprez, et al., Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression, *Genome Biol.* 17 (1) (2016) 218, <https://doi.org/10.1186/s13059-016-1070-5>.
- [16] S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, *BMC Bioinform.* 14 (2013) 7, <https://doi.org/10.1186/1471-2105-14-7>.
- [17] Z. Gu, R. Eils, M. Schlesner, Complex heatmaps reveal patterns and correlations in multidimensional genomic data, *Bioinformatics* 32 (18) (2016) 2847–2849, <https://doi.org/10.1093/bioinformatics/btw313>.
- [18] K. Yoshihara, M. Shahmoradgoli, E. Martinez, R. Vegesna, H. Kim, W. Torres-Garcia, et al., Inferring tumour purity and stromal and immune cell admixture from expression data, *Nat. Commun.* 4 (2013) 2612, <https://doi.org/10.1038/ncomms3612>.
- [19] Y. Senbabaoglu, R.S. Gejman, A.G. Winer, M. Liu, E.M. Van Allen, G. de Velasco, et al., Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures, *Genome Biol.* 17 (1) (2016) 231, <https://doi.org/10.1186/s13059-016-1092-z>.
- [20] M.S. Rooney, S.A. Shukla, C.J. Wu, G. Getz, N. Hacohen, Molecular and genetic properties of tumors associated with local immune cytolytic activity, *Cell* 160 (1–2) (2015) 48–61, <https://doi.org/10.1016/j.cell.2014.12.033>.
- [21] G. Yu, L.G. Wang, Y. Han, Q.Y. He, clusterProfiler: an R package for comparing biological themes among gene clusters, *OMICS* 16 (5) (2012) 284–287, <https://doi.org/10.1089/omi.2011.0118>.

- [22] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, *Proc. Natl. Acad. Sci. USA* 102 (43) (2005) 15545–15550, <https://doi.org/10.1073/pnas.0506580102>.
- [23] A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J.P. Mesirov, P. Tamayo, The molecular signatures database (MSigDB) hallmark gene set collection, *Cell Syst.* 1 (6) (2015) 417–425, <https://doi.org/10.1016/j.cels.2015.12.004>.
- [24] M. Pertea, D. Kim, G.M. Pertea, J.T. Leek, S.L. Salzberg, Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown, *Nat. Protoc.* 11 (9) (2016) 1650–1667, <https://doi.org/10.1038/nprot.2016.095>.
- [25] K. Vitting-Seerup, A. Sandelin, IsoformSwitchAnalyzeR: analysis of changes in genome-wide patterns of alternative splicing and its functional consequences, *Bioinformatics* 35 (21) (2019) 4469–4471, <https://doi.org/10.1093/bioinformatics/btz247>.
- [26] D. Szklarczyk, A.L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, et al., STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, *Nucleic Acids Res.* 47 (D1) (2019) D607–DD13, <https://doi.org/10.1093/nar/gky1131>.
- [27] C.H. Chin, S.H. Chen, H.H. Wu, C.W. Ho, M.T. Ko, C.Y. Lin, cytoHubba: identifying hub objects and sub-networks from complex interactome, *BMC Syst. Biol.* 8 (Suppl 4) (2014) S11, <https://doi.org/10.1186/1752-0509-8-S4-S11>.
- [28] P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, et al., Cytoscape: a software environment for integrated models of biomolecular interaction networks, *Genome Res.* 13 (11) (2003) 2498–2504, <https://doi.org/10.1101/gr.1239303>.
- [29] R. Mandal, Y. Senbabaoglu, A. Desrichard, J.J. Havel, M.G. Dalin, N. Riaz, et al., The head and neck cancer immune landscape and its immunotherapeutic implications, *JCI Insight* 1 (17) (2016) e89829, <https://doi.org/10.1172/jci.insight.89829>.
- [30] A.C. Birkeland, S.K. Foltin, N.L. Michmerhuizen, R.C. Hoesli, A.J. Rosko, S. Byrd, et al., Correlation of Crtcl/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma, *Oral Oncol.* 68 (2017) 5–8, <https://doi.org/10.1016/j.oraloncology.2017.02.025>.
- [31] M. Yang, J. Lu, G. Zhang, Y. Wang, M. He, Q. Xu, et al., CXCL13 shapes immunoreactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer, *J. Immunother. Cancer* 9 (1) (2021), <https://doi.org/10.1136/jitc-2020-001136>.
- [32] S.Y. Cho, S. Kim, M.J. Son, G. Kim, P. Singh, H.N. Kim, et al., Dual oxidase 1 and NADPH oxidase 2 exert favorable effects in cervical cancer patients by activating immune response, *BMC Cancer* 19 (1) (2019) 1078, <https://doi.org/10.1186/s12885-019-6202-3>.
- [33] P. Lu, V.M. Weaver, Z. Werb, The extracellular matrix: a dynamic niche in cancer progression, *J. Cell Biol.* 196 (4) (2012) 395–406, <https://doi.org/10.1083/jcb.201102147>.
- [34] D. Yan, A.O. Adeshakin, M. Xu, L.O. Afolabi, G. Zhang, Y.H. Chen, et al., Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in tumor, *Front. Immunol.* 10 (2019) 1399, <https://doi.org/10.3389/fimmu.2019.01399>.
- [35] L. Jiang, X. Fang, H. Wang, D. Li, X. Wang, Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells, *Front. Immunol.* 9 (2018) 2927, <https://doi.org/10.3389/fimmu.2018.02927>.
- [36] L. Gonzalez-Gonzalez, J. Alonso, Periostin: a matricellular protein with multiple functions in cancer development and progression, *Front. Oncol.* 8 (2018) 225, <https://doi.org/10.3389/fonc.2018.00225>.
- [37] Y. Bai, M. Nakamura, G. Zhou, Y. Li, Z. Liu, T. Ozaki, et al., Novel isoforms of periostin expressed in the human thyroid, *Jpn. Clin. Med.* 1 (2010) 13–20, <https://doi.org/10.4137/JCM.S5899>.
- [38] T. Kawane, X. Qin, Q. Jiang, T. Miyazaki, H. Komori, C.A. Yoshida, et al., Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3, *Sci. Rep.* 8 (1) (2018) 13551, <https://doi.org/10.1038/s41598-018-31853-0>.
- [39] J.A. Eddy, V. Thorsson, A.E. Lamb, D.L. Gibbs, C. Heimann, J.X. Yu, et al., CRI iAtlas: an interactive portal for immuno-oncology research, *F1000Res* 9 (2020) 1028, <https://doi.org/10.12688/f1000research.25141.1>.
- [40] P.C. McDonald, S.C. Chafe, W.S. Brown, S. Saberi, M. Swayampakula, G. Venkateswaran, et al., Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia, *Gastroenterology* 157 (3) (2019) 823–837, <https://doi.org/10.1053/j.gastro.2019.05.004>.
- [41] M.S. Haas, M.H. Kagey, H. Heath, F. Schuerpf, J.B. Rottman, W. Newman, mDKN-01, a novel anti-DKK1 mAb, enhances innate immune responses in the tumor microenvironment, *Mol. Cancer Res.* 19 (4) (2021) 717–725, <https://doi.org/10.1158/1541-7786.MCR-20-0799>.
- [42] F. Baenke, B. Peck, H. Miess, A. Schulze, Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development, *Dis. Model. Mech.* 6 (6) (2013) 1353–1363, <https://doi.org/10.1242/dmm.011338>.
- [43] S. Tiwary, J.A. Berzofsky, M. Terabe, Altered lipid tumor environment and its potential effects on NKT cell function in tumor immunity, *Front. Immunol.* 10 (2019) 2187, <https://doi.org/10.3389/fimmu.2019.02187>.
- [44] R.E. Airley, P. McHugh, A.R. Evans, B. Harris, L. Winchester, F.M. Buffa, et al., Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression, *Br. J. Cancer* 110 (3) (2014) 715–723, <https://doi.org/10.1038/bjc.2013.765>.
- [45] A. Adams, K. Warner, J.E. Nor, Salivary gland cancer stem cells, *Oral Oncol.* 49 (9) (2013) 845–853, <https://doi.org/10.1016/j.oraloncology.2013.05.013>.
- [46] R. Maurya, P. Bhattacharya, R. Dey, H.L. Nakhasi, Leptin functions in infectious diseases, *Front. Immunol.* 9 (2018) 2741, <https://doi.org/10.3389/fimmu.2018.02741>.